Genentech, Lexicon Genetics Inc. deal

The partners expanded a 2002 drug discovery deal under which LEXG was researching the functions and potential uses of genes identified by DNA. LEXG will now conduct advanced research on targets from DNA's Secreted Protein Discovery Initiative (SPDI) program that have been validated using LEXG's gene knockout technology. LEXG may develop and commercialize therapeutics against up to six of the targets. DNA retains an option to develop these products under a cost and profit sharing arrangement, under which LEXG would have certain worldwide co-promotion rights. LEXG has started preclinical studies on two such targets for metabolic diseases. ...